Poseida Therapeutics (NASDAQ:PSTX) Price Target Raised to $20.00

Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its target price upped by HC Wainwright from $15.00 to $20.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald […]

Related Keywords

,Lazard Asset Management ,Cantor Fitzgerald ,Poseida Therapeutics Company Profile ,Poseida Therapeutics Inc ,Mackenzie Financial Corp ,Proshare Advisors ,Allspring Global Investments Holdings ,Poseida Therapeutics ,Free Report ,Poseida Therapeutic ,Get Free Report ,Share Advisors ,Global Investments Holdings ,Asset Management ,Financial Corp ,Poseida Therapeutics Daily ,Nasdaq Pstx ,Pstx ,Medical ,Boost Price Target ,Hc Wainwright ,